Study of HLA-Haploidentical Stem Cell Transplantation to Treat Clinically Aggressive Sickle Cell Disease

Abroad (travel likely)RecruitingPHASE2

Conditions

Sickle Cell Disease

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

University of Illinois at Chicago, Chicago, Illinois, United States
Contact: Study coordinator (Damiano Rondelli, MD) · drond@uic.edu · 312-413-3547

Study leads

Damiano Rondelli, MD
Principal Investigator
University of Illinois at Chicago

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

A Study of Immune Suppression Treatment for People With Sickle Cell Disease or β-Thalassemia Who Are Going to Receive an Allogeneic Hematopoietic Cell Transplantation (HCT)

Sickle Cell Disease · Thalassemia, Beta · Thalassemia

Abroad (travel likely)RecruitingPHASE2

Basking Ridge, United States · Middletown, United States

Nonmyeloablative Stem Cell Transplant in Children With Sickle Cell Disease and a Major ABO-Incompatible Matched Sibling Donor

Sickle Cell Disease · Stem Cell Transplant Complications · Red Blood Cell Disorder

Abroad (travel likely)RecruitingPHASE2

Calgary, Canada

Sickle Cell Disease Transplant Using a Nonmyeloablative Approach for Patients With Anti-donor Red Cell Antibody

Sickle Cell Disease

Abroad (travel likely)RecruitingPHASE2

Washington D.C., United States

Alendronate for Osteonecrosis in Adults With Sickle Cell Disease

Sickle Cell Disease · Sickle Cell Anemia · Osteonecrosis

Abroad (travel likely)RecruitingPHASE2

Sacramento, United States